サンプル依頼リスト カート
  • English
デフォルト表紙
市場調査レポート
商品コード
1757940

アジソン病治療薬の世界市場

Addison's Disease Therapeutics

出版日
ページ情報
英文 278 Pages
納期
即日から翌営業日
適宜更新あり
価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=145.63円
アジソン病治療薬の世界市場
出版日: 2025年06月27日
発行: Global Industry Analysts, Inc.
ページ情報: 英文 278 Pages
納期: 即日から翌営業日
GIIご利用のメリット
  • 全表示
  • 概要
  • 目次
概要

アジソン病治療薬の世界市場は2030年までに9億4,830万米ドルに達する見込み

2024年に6億8,140万米ドルと推定されるアジソン病治療薬の世界市場は、2024～2030年の分析期間においてCAGR 5.7%で成長し、2030年には9億4,830万米ドルに達すると予測されます。本レポートで分析したセグメントの1つである経口薬は、CAGR 6.6%を記録し、分析期間終了時には6億6,140万米ドルに達すると予測されます。非経口薬セグメントは、分析期間中CAGR 3.7%の成長が見込まれます。

米国市場は1億8,570万米ドルと推定、中国はCAGR 9.1％で成長予測

米国のアジソン病治療薬市場は2024年に1億8,570万米ドルと推定されます。世界第2位の経済大国である中国は、2024年から2030年の分析期間においてCAGR 9.1%で推移し、2030年には1億9,320万米ドルの市場規模に達すると予測されています。その他の注目すべき地域別市場としては、日本とカナダがあり、分析期間中のCAGRはそれぞれ2.7%と5.6%と予測されています。欧州では、ドイツがCAGR 3.7%で成長すると予測されています。

アジソン病治療薬の世界市場- 主要動向と促進要因のまとめ

アジソン病治療薬が内分泌学、希少疾患管理、ホルモン補充イノベーションの各分野で戦略的重要性を増しているのはなぜか？

アジソン病（原発性副腎不全）は、副腎が十分なコルチゾールと、多くの場合アルドステロンを産生できないことを特徴とするまれな内分泌疾患です。このホルモン欠乏は、疲労、体重減少、低血圧、色素沈着などの症状を引き起こします。適切な治療がなければ、患者は、特にストレスや病気の時期に、生命を脅かす副腎クリーゼを起こす危険性があります。

アジソン病が患者のQOLに与える影響と重篤な合併症の可能性が認識されるようになり、効果的な治療戦略の必要性が強調されるようになりました。診断技術の進歩により早期発見が可能になり、また、ホルモン補充療法に関する現在進行中の研究は、自然のホルモンリズムをよりよく模倣することで、患者の予後を改善することを目指しています。

徐放性製剤、輸液技術、個別化された投与プロトコールは、アジソン病管理をどのように変革しているか？

従来のアジソン病治療には、生涯にわたるホルモン補充療法が必要でした。コルチゾールは通常、ヒドロコルチゾン、プレドニゾン、デキサメタゾンなどの経口グルココルチコイドで補充され、自然の概日リズムをシミュレートするために1日2～3回投与されます。アルドステロン欠乏症には酢酸フルドロコルチゾンが用いられます。

新しい治療法は、コルチゾール分泌の生理学的模倣を改善することに焦点をあてています。一日を通してより安定したコルチゾールレベルを提供するために、徐放性ヒドロコルチゾン製剤や携帯ポンプを用いたヒドロコルチゾン持続皮下注入（CSHI）が開発されています。これらのアプローチは、投与回数を減らし、従来の治療に伴うピークとトラフを最小限に抑えることを目的としています。

PULSES試験のような臨床試験では、CSHIが患者の幸福感、エネルギーレベル、全体的なQOLを有意に改善することが実証されています。患者は、従来の経口投与よりも輸液療法を好むと報告し、より良好な症状コントロールと疲労の軽減を挙げています。

先進的アジソン病治療薬の需要を牽引している患者集団、臨床現場、地域市場は？

アジソン病はまれな疾患であり、米国では約10万人に1人が罹患しているが、中年女性や他の自己免疫疾患を有する患者など、特定の集団は罹患しやすいです。効果的な管理戦略の必要性は、これらのグループや治療を複雑にする併存疾患を持つ患者において特に深刻です。

北米と欧州のヘルスケアシステムは、強固な医療インフラと保険償還の枠組みに支えられ、先進的な治療法を採用する最前線にあります。これとは対照的に、アジア、アフリカ、ラテンアメリカの多くの地域では、専門的な治療法へのアクセスが依然として限られており、医療格差に対処するための世界ヘルスイニシアチブの必要性が浮き彫りになっています。

アジソン病治療薬は、ホルモン補充療法、患者中心のケア、希少疾患研究といった幅広い文脈において、どのような戦略的役割を果たすのか？

アジソン病治療薬の進歩は、内分泌学における個別化医療と患者中心のケアへのシフトを例証するものです。治療レジメンを個々の患者のニーズに合わせて調整し、自然のホルモンパターンを忠実に再現する技術を活用することで、臨床医は治療成績を改善し、罹患者の生活の質を高めることができます。

さらに、アジソン病に関する調査は、自己免疫疾患とホルモン補充療法に関する幅広い理解に貢献します。この疾患の管理から得られた知見は、他の副腎不全や内分泌疾患の治療アプローチに反映され、この分野全体の技術革新を促進します。

ヘルスケアがより個別化され、技術的に統合されたモデルへと進化し続ける中、アジソン病管理における革新は、他の希少疾患や慢性疾患におけるケアを進歩させるための青写真となり得るのだろうか？

セグメント

治療（経口薬、非経口薬）;エンドユース（病院・診療所エンドユース、診断ラボエンドユース）

調査対象企業の例（全47件）

  • Alexion Pharmaceuticals
  • Amryt Pharma
  • AstraZeneca
  • BioMarin Pharmaceutical
  • Bristol-Myers Squibb
  • Chiasma
  • Ferring Pharmaceuticals
  • HRA Pharma
  • Horizon Therapeutics
  • Ipsen
  • Mallinckrodt Pharmaceuticals
  • Mylan（now part of Viatris）
  • Novartis
  • Novo Nordisk
  • Perrigo Company
  • Pfizer
  • Recordati
  • Sanofi
  • Shire（part of Takeda）
  • Teva Pharmaceutical

AI統合

当社は、有効な専門家コンテンツとAIツールにより、市場情報と競合情報を変革しています。

Global Industry Analystsは、LLMや業界固有のSLMを照会する一般的な規範に従う代わりに、ビデオ記録、ブログ、検索エンジン調査、膨大な量の企業、製品/サービス、市場データなど、世界中の専門家から収集したコンテンツのリポジトリを構築しました。

関税影響係数

Global Industry Analystsは、本社の国、製造拠点、輸出入（完成品とOEM）に基づく企業の競争力の変化を予測しています。この複雑で多面的な市場力学は、売上原価（COGS）の増加、収益性の低下、サプライチェーンの再構築など、ミクロおよびマクロの市場力学の中でも特に競合他社に影響を与える見込みです。

目次

第1章 調査手法

第2章 エグゼクティブサマリー

  • 市場概要
  • 主要企業
  • 市場動向と促進要因
  • 世界市場の見通し

第3章 市場分析

  • 米国
  • カナダ
  • 日本
  • 中国
  • 欧州
  • フランス
  • ドイツ
  • イタリア
  • 英国
  • スペイン
  • ロシア
  • その他欧州
  • アジア太平洋
  • オーストラリア
  • インド
  • 韓国
  • その他アジア太平洋地域
  • ラテンアメリカ
  • アルゼンチン
  • ブラジル
  • メキシコ
  • その他ラテンアメリカ
  • 中東
  • イラン
  • イスラエル
  • サウジアラビア
  • アラブ首長国連邦
  • その他中東
  • アフリカ

第4章 競合

目次
Product Code: MCP36069

Global Addison's Disease Therapeutics Market to Reach US$948.3 Million by 2030

The global market for Addison's Disease Therapeutics estimated at US$681.4 Million in the year 2024, is expected to reach US$948.3 Million by 2030, growing at a CAGR of 5.7% over the analysis period 2024-2030. Oral Drugs, one of the segments analyzed in the report, is expected to record a 6.6% CAGR and reach US$661.4 Million by the end of the analysis period. Growth in the Parenteral Drugs segment is estimated at 3.7% CAGR over the analysis period.

The U.S. Market is Estimated at US$185.7 Million While China is Forecast to Grow at 9.1% CAGR

The Addison's Disease Therapeutics market in the U.S. is estimated at US$185.7 Million in the year 2024. China, the world's second largest economy, is forecast to reach a projected market size of US$193.2 Million by the year 2030 trailing a CAGR of 9.1% over the analysis period 2024-2030. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at a CAGR of 2.7% and 5.6% respectively over the analysis period. Within Europe, Germany is forecast to grow at approximately 3.7% CAGR.

Global Addison’s Disease Therapeutics Market - Key Trends & Drivers Summarized

Why Are Addison’s Disease Therapeutics Gaining Strategic Importance Across Endocrinology, Rare Disease Management, and Hormone Replacement Innovation?

Addison’s disease, or primary adrenal insufficiency, is a rare endocrine disorder characterized by the adrenal glands' inability to produce sufficient cortisol and, in many cases, aldosterone. This hormonal deficiency can lead to symptoms such as fatigue, weight loss, low blood pressure, and hyperpigmentation. Without appropriate treatment, patients are at risk of life-threatening adrenal crises, especially during periods of stress or illness .

The increasing recognition of Addison’s disease's impact on patient quality of life and the potential for severe complications has underscored the need for effective therapeutic strategies. Advances in diagnostic techniques have improved early detection, while ongoing research into hormone replacement therapies aims to better mimic natural hormonal rhythms, thereby enhancing patient outcomes.

How Are Modified-Release Formulations, Infusion Technologies, and Personalized Dosing Protocols Transforming Addison’s Disease Management?

Traditional treatment for Addison’s disease involves lifelong hormone replacement therapy. Cortisol is typically replaced with oral glucocorticoids such as hydrocortisone, prednisone, or dexamethasone, administered two to three times daily to simulate natural circadian rhythms. Aldosterone deficiency is managed with fludrocortisone acetate .

Emerging therapies focus on improving the physiological mimicry of cortisol secretion. Modified-release hydrocortisone formulations and continuous subcutaneous hydrocortisone infusion (CSHI) via portable pumps have been developed to provide more stable cortisol levels throughout the day. These approaches aim to reduce the frequency of dosing and minimize peaks and troughs associated with conventional therapy .

Clinical trials, such as the PULSES study, have demonstrated that CSHI can significantly improve patient well-being, energy levels, and overall quality of life. Patients reported a preference for infusion therapy over traditional oral dosing, citing better symptom control and reduced fatigue .

Which Patient Populations, Clinical Settings, and Regional Markets Are Driving Demand for Advanced Addison’s Disease Therapeutics?

While Addison’s disease is rare, affecting approximately 1 in 100,000 individuals in the U.S., certain populations are more susceptible, including middle-aged women and individuals with other autoimmune conditions. The need for effective management strategies is particularly acute in these groups, as well as in patients with comorbidities that complicate treatment .

Healthcare systems in North America and Europe are at the forefront of adopting advanced therapies, supported by robust healthcare infrastructure and reimbursement frameworks. In contrast, access to specialized treatments remains limited in many parts of Asia, Africa, and Latin America, highlighting the need for global health initiatives to address disparities in care.

What Strategic Role Will Addison’s Disease Therapeutics Play in the Broader Context of Hormone Replacement Therapy, Patient-Centered Care, and Rare Disease Research?

Advancements in Addison’s disease therapeutics exemplify the shift toward personalized medicine and patient-centered care in endocrinology. By tailoring treatment regimens to individual patient needs and leveraging technologies that closely replicate natural hormone patterns, clinicians can improve outcomes and enhance quality of life for those affected.

Furthermore, research into Addison’s disease contributes to the broader understanding of autoimmune disorders and hormone replacement therapy. Insights gained from managing this condition can inform treatment approaches for other forms of adrenal insufficiency and endocrine disorders, fostering innovation across the field.

As healthcare continues to evolve toward more individualized and technologically integrated models, could the innovations in Addison’s disease management serve as a blueprint for advancing care in other rare and chronic conditions?

SCOPE OF STUDY:

The report analyzes the Addison's Disease Therapeutics market in terms of units by the following Segments, and Geographic Regions/Countries:

Segments:

Therapy (Oral Drugs, Parenteral Drugs); End-Use (Hospitals & Clinics End-Use, Diagnostic Laboratories End-Use)

Geographic Regions/Countries:

World; United States; Canada; Japan; China; Europe (France; Germany; Italy; United Kingdom; Spain; Russia; and Rest of Europe); Asia-Pacific (Australia; India; South Korea; and Rest of Asia-Pacific); Latin America (Argentina; Brazil; Mexico; and Rest of Latin America); Middle East (Iran; Israel; Saudi Arabia; United Arab Emirates; and Rest of Middle East); and Africa.

Select Competitors (Total 47 Featured) -

  • Alexion Pharmaceuticals
  • Amryt Pharma
  • AstraZeneca
  • BioMarin Pharmaceutical
  • Bristol-Myers Squibb
  • Chiasma
  • Ferring Pharmaceuticals
  • HRA Pharma
  • Horizon Therapeutics
  • Ipsen
  • Mallinckrodt Pharmaceuticals
  • Mylan (now part of Viatris)
  • Novartis
  • Novo Nordisk
  • Perrigo Company
  • Pfizer
  • Recordati
  • Sanofi
  • Shire (part of Takeda)
  • Teva Pharmaceutical

AI INTEGRATIONS

We're transforming market and competitive intelligence with validated expert content and AI tools.

Instead of following the general norm of querying LLMs and Industry-specific SLMs, we built repositories of content curated from domain experts worldwide including video transcripts, blogs, search engines research, and massive amounts of enterprise, product/service, and market data.

TARIFF IMPACT FACTOR

Our new release incorporates impact of tariffs on geographical markets as we predict a shift in competitiveness of companies based on HQ country, manufacturing base, exports and imports (finished goods and OEM). This intricate and multifaceted market reality will impact competitors by increasing the Cost of Goods Sold (COGS), reducing profitability, reconfiguring supply chains, amongst other micro and macro market dynamics.

TABLE OF CONTENTS

I. METHODOLOGY

II. EXECUTIVE SUMMARY

  • 1. MARKET OVERVIEW
    • Influencer Market Insights
    • World Market Trajectories
    • Addison's Disease Therapeutics - Global Key Competitors Percentage Market Share in 2025 (E)
    • Competitive Market Presence - Strong/Active/Niche/Trivial for Players Worldwide in 2025 (E)
  • 2. FOCUS ON SELECT PLAYERS
  • 3. MARKET TRENDS & DRIVERS
    • Rising Awareness of Adrenal Insufficiency Conditions Throws the Spotlight on Addisons Disease Therapeutics
    • Growth in Autoimmune Disorder Diagnosis Drives Targeted Hormone Replacement Therapy Use
    • Increased Demand for Injectable Crisis Medication Supports Emergency Preparedness in Patients
    • Integration of Digital Health Platforms for Dose Management Enhances Patient Monitoring
    • Expansion of Personalized Dosing Algorithms Promotes Individualized Hormone Balancing
    • OEMs Offering Hydrocortisone Delivery Devices Improve Self-Administration Accuracy
    • Education Campaigns and Endocrinology Awareness Boost Early Diagnosis and Adherence
    • Growth in Pediatric and Geriatric Patient Segments Spurs Age-Specific Formulations
  • 4. GLOBAL MARKET PERSPECTIVE
    • TABLE 1: World Addison's Disease Therapeutics Market Analysis of Annual Sales in US$ Thousand for Years 2014 through 2030
    • TABLE 2: World Recent Past, Current & Future Analysis for Addison's Disease Therapeutics by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 3: World Historic Review for Addison's Disease Therapeutics by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 4: World 16-Year Perspective for Addison's Disease Therapeutics by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets for Years 2014, 2025 & 2030
    • TABLE 5: World Recent Past, Current & Future Analysis for Oral Drugs by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 6: World Historic Review for Oral Drugs by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 7: World 16-Year Perspective for Oral Drugs by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2025 & 2030
    • TABLE 8: World Recent Past, Current & Future Analysis for Parenteral Drugs by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 9: World Historic Review for Parenteral Drugs by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 10: World 16-Year Perspective for Parenteral Drugs by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2025 & 2030
    • TABLE 11: World Recent Past, Current & Future Analysis for Hospitals & Clinics End-Use by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 12: World Historic Review for Hospitals & Clinics End-Use by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 13: World 16-Year Perspective for Hospitals & Clinics End-Use by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2025 & 2030
    • TABLE 14: World Recent Past, Current & Future Analysis for Diagnostic Laboratories End-Use by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 15: World Historic Review for Diagnostic Laboratories End-Use by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 16: World 16-Year Perspective for Diagnostic Laboratories End-Use by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2025 & 2030

III. MARKET ANALYSIS

  • UNITED STATES
    • Addison's Disease Therapeutics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United States for 2025 (E)
    • TABLE 17: USA Recent Past, Current & Future Analysis for Addison's Disease Therapeutics by Therapy - Oral Drugs and Parenteral Drugs - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 18: USA Historic Review for Addison's Disease Therapeutics by Therapy - Oral Drugs and Parenteral Drugs Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 19: USA 16-Year Perspective for Addison's Disease Therapeutics by Therapy - Percentage Breakdown of Value Sales for Oral Drugs and Parenteral Drugs for the Years 2014, 2025 & 2030
    • TABLE 20: USA Recent Past, Current & Future Analysis for Addison's Disease Therapeutics by End-Use - Hospitals & Clinics End-Use and Diagnostic Laboratories End-Use - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 21: USA Historic Review for Addison's Disease Therapeutics by End-Use - Hospitals & Clinics End-Use and Diagnostic Laboratories End-Use Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 22: USA 16-Year Perspective for Addison's Disease Therapeutics by End-Use - Percentage Breakdown of Value Sales for Hospitals & Clinics End-Use and Diagnostic Laboratories End-Use for the Years 2014, 2025 & 2030
  • CANADA
    • TABLE 23: Canada Recent Past, Current & Future Analysis for Addison's Disease Therapeutics by Therapy - Oral Drugs and Parenteral Drugs - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 24: Canada Historic Review for Addison's Disease Therapeutics by Therapy - Oral Drugs and Parenteral Drugs Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 25: Canada 16-Year Perspective for Addison's Disease Therapeutics by Therapy - Percentage Breakdown of Value Sales for Oral Drugs and Parenteral Drugs for the Years 2014, 2025 & 2030
    • TABLE 26: Canada Recent Past, Current & Future Analysis for Addison's Disease Therapeutics by End-Use - Hospitals & Clinics End-Use and Diagnostic Laboratories End-Use - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 27: Canada Historic Review for Addison's Disease Therapeutics by End-Use - Hospitals & Clinics End-Use and Diagnostic Laboratories End-Use Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 28: Canada 16-Year Perspective for Addison's Disease Therapeutics by End-Use - Percentage Breakdown of Value Sales for Hospitals & Clinics End-Use and Diagnostic Laboratories End-Use for the Years 2014, 2025 & 2030
  • JAPAN
    • Addison's Disease Therapeutics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Japan for 2025 (E)
    • TABLE 29: Japan Recent Past, Current & Future Analysis for Addison's Disease Therapeutics by Therapy - Oral Drugs and Parenteral Drugs - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 30: Japan Historic Review for Addison's Disease Therapeutics by Therapy - Oral Drugs and Parenteral Drugs Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 31: Japan 16-Year Perspective for Addison's Disease Therapeutics by Therapy - Percentage Breakdown of Value Sales for Oral Drugs and Parenteral Drugs for the Years 2014, 2025 & 2030
    • TABLE 32: Japan Recent Past, Current & Future Analysis for Addison's Disease Therapeutics by End-Use - Hospitals & Clinics End-Use and Diagnostic Laboratories End-Use - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 33: Japan Historic Review for Addison's Disease Therapeutics by End-Use - Hospitals & Clinics End-Use and Diagnostic Laboratories End-Use Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 34: Japan 16-Year Perspective for Addison's Disease Therapeutics by End-Use - Percentage Breakdown of Value Sales for Hospitals & Clinics End-Use and Diagnostic Laboratories End-Use for the Years 2014, 2025 & 2030
  • CHINA
    • Addison's Disease Therapeutics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in China for 2025 (E)
    • TABLE 35: China Recent Past, Current & Future Analysis for Addison's Disease Therapeutics by Therapy - Oral Drugs and Parenteral Drugs - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 36: China Historic Review for Addison's Disease Therapeutics by Therapy - Oral Drugs and Parenteral Drugs Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 37: China 16-Year Perspective for Addison's Disease Therapeutics by Therapy - Percentage Breakdown of Value Sales for Oral Drugs and Parenteral Drugs for the Years 2014, 2025 & 2030
    • TABLE 38: China Recent Past, Current & Future Analysis for Addison's Disease Therapeutics by End-Use - Hospitals & Clinics End-Use and Diagnostic Laboratories End-Use - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 39: China Historic Review for Addison's Disease Therapeutics by End-Use - Hospitals & Clinics End-Use and Diagnostic Laboratories End-Use Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 40: China 16-Year Perspective for Addison's Disease Therapeutics by End-Use - Percentage Breakdown of Value Sales for Hospitals & Clinics End-Use and Diagnostic Laboratories End-Use for the Years 2014, 2025 & 2030
  • EUROPE
    • Addison's Disease Therapeutics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Europe for 2025 (E)
    • TABLE 41: Europe Recent Past, Current & Future Analysis for Addison's Disease Therapeutics by Geographic Region - France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 42: Europe Historic Review for Addison's Disease Therapeutics by Geographic Region - France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 43: Europe 16-Year Perspective for Addison's Disease Therapeutics by Geographic Region - Percentage Breakdown of Value Sales for France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets for Years 2014, 2025 & 2030
    • TABLE 44: Europe Recent Past, Current & Future Analysis for Addison's Disease Therapeutics by Therapy - Oral Drugs and Parenteral Drugs - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 45: Europe Historic Review for Addison's Disease Therapeutics by Therapy - Oral Drugs and Parenteral Drugs Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 46: Europe 16-Year Perspective for Addison's Disease Therapeutics by Therapy - Percentage Breakdown of Value Sales for Oral Drugs and Parenteral Drugs for the Years 2014, 2025 & 2030
    • TABLE 47: Europe Recent Past, Current & Future Analysis for Addison's Disease Therapeutics by End-Use - Hospitals & Clinics End-Use and Diagnostic Laboratories End-Use - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 48: Europe Historic Review for Addison's Disease Therapeutics by End-Use - Hospitals & Clinics End-Use and Diagnostic Laboratories End-Use Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 49: Europe 16-Year Perspective for Addison's Disease Therapeutics by End-Use - Percentage Breakdown of Value Sales for Hospitals & Clinics End-Use and Diagnostic Laboratories End-Use for the Years 2014, 2025 & 2030
  • FRANCE
    • Addison's Disease Therapeutics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in France for 2025 (E)
    • TABLE 50: France Recent Past, Current & Future Analysis for Addison's Disease Therapeutics by Therapy - Oral Drugs and Parenteral Drugs - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 51: France Historic Review for Addison's Disease Therapeutics by Therapy - Oral Drugs and Parenteral Drugs Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 52: France 16-Year Perspective for Addison's Disease Therapeutics by Therapy - Percentage Breakdown of Value Sales for Oral Drugs and Parenteral Drugs for the Years 2014, 2025 & 2030
    • TABLE 53: France Recent Past, Current & Future Analysis for Addison's Disease Therapeutics by End-Use - Hospitals & Clinics End-Use and Diagnostic Laboratories End-Use - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 54: France Historic Review for Addison's Disease Therapeutics by End-Use - Hospitals & Clinics End-Use and Diagnostic Laboratories End-Use Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 55: France 16-Year Perspective for Addison's Disease Therapeutics by End-Use - Percentage Breakdown of Value Sales for Hospitals & Clinics End-Use and Diagnostic Laboratories End-Use for the Years 2014, 2025 & 2030
  • GERMANY
    • Addison's Disease Therapeutics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Germany for 2025 (E)
    • TABLE 56: Germany Recent Past, Current & Future Analysis for Addison's Disease Therapeutics by Therapy - Oral Drugs and Parenteral Drugs - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 57: Germany Historic Review for Addison's Disease Therapeutics by Therapy - Oral Drugs and Parenteral Drugs Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 58: Germany 16-Year Perspective for Addison's Disease Therapeutics by Therapy - Percentage Breakdown of Value Sales for Oral Drugs and Parenteral Drugs for the Years 2014, 2025 & 2030
    • TABLE 59: Germany Recent Past, Current & Future Analysis for Addison's Disease Therapeutics by End-Use - Hospitals & Clinics End-Use and Diagnostic Laboratories End-Use - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 60: Germany Historic Review for Addison's Disease Therapeutics by End-Use - Hospitals & Clinics End-Use and Diagnostic Laboratories End-Use Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 61: Germany 16-Year Perspective for Addison's Disease Therapeutics by End-Use - Percentage Breakdown of Value Sales for Hospitals & Clinics End-Use and Diagnostic Laboratories End-Use for the Years 2014, 2025 & 2030
  • ITALY
    • TABLE 62: Italy Recent Past, Current & Future Analysis for Addison's Disease Therapeutics by Therapy - Oral Drugs and Parenteral Drugs - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 63: Italy Historic Review for Addison's Disease Therapeutics by Therapy - Oral Drugs and Parenteral Drugs Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 64: Italy 16-Year Perspective for Addison's Disease Therapeutics by Therapy - Percentage Breakdown of Value Sales for Oral Drugs and Parenteral Drugs for the Years 2014, 2025 & 2030
    • TABLE 65: Italy Recent Past, Current & Future Analysis for Addison's Disease Therapeutics by End-Use - Hospitals & Clinics End-Use and Diagnostic Laboratories End-Use - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 66: Italy Historic Review for Addison's Disease Therapeutics by End-Use - Hospitals & Clinics End-Use and Diagnostic Laboratories End-Use Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 67: Italy 16-Year Perspective for Addison's Disease Therapeutics by End-Use - Percentage Breakdown of Value Sales for Hospitals & Clinics End-Use and Diagnostic Laboratories End-Use for the Years 2014, 2025 & 2030
  • UNITED KINGDOM
    • Addison's Disease Therapeutics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United Kingdom for 2025 (E)
    • TABLE 68: UK Recent Past, Current & Future Analysis for Addison's Disease Therapeutics by Therapy - Oral Drugs and Parenteral Drugs - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 69: UK Historic Review for Addison's Disease Therapeutics by Therapy - Oral Drugs and Parenteral Drugs Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 70: UK 16-Year Perspective for Addison's Disease Therapeutics by Therapy - Percentage Breakdown of Value Sales for Oral Drugs and Parenteral Drugs for the Years 2014, 2025 & 2030
    • TABLE 71: UK Recent Past, Current & Future Analysis for Addison's Disease Therapeutics by End-Use - Hospitals & Clinics End-Use and Diagnostic Laboratories End-Use - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 72: UK Historic Review for Addison's Disease Therapeutics by End-Use - Hospitals & Clinics End-Use and Diagnostic Laboratories End-Use Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 73: UK 16-Year Perspective for Addison's Disease Therapeutics by End-Use - Percentage Breakdown of Value Sales for Hospitals & Clinics End-Use and Diagnostic Laboratories End-Use for the Years 2014, 2025 & 2030
  • SPAIN
    • TABLE 74: Spain Recent Past, Current & Future Analysis for Addison's Disease Therapeutics by Therapy - Oral Drugs and Parenteral Drugs - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 75: Spain Historic Review for Addison's Disease Therapeutics by Therapy - Oral Drugs and Parenteral Drugs Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 76: Spain 16-Year Perspective for Addison's Disease Therapeutics by Therapy - Percentage Breakdown of Value Sales for Oral Drugs and Parenteral Drugs for the Years 2014, 2025 & 2030
    • TABLE 77: Spain Recent Past, Current & Future Analysis for Addison's Disease Therapeutics by End-Use - Hospitals & Clinics End-Use and Diagnostic Laboratories End-Use - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 78: Spain Historic Review for Addison's Disease Therapeutics by End-Use - Hospitals & Clinics End-Use and Diagnostic Laboratories End-Use Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 79: Spain 16-Year Perspective for Addison's Disease Therapeutics by End-Use - Percentage Breakdown of Value Sales for Hospitals & Clinics End-Use and Diagnostic Laboratories End-Use for the Years 2014, 2025 & 2030
  • RUSSIA
    • TABLE 80: Russia Recent Past, Current & Future Analysis for Addison's Disease Therapeutics by Therapy - Oral Drugs and Parenteral Drugs - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 81: Russia Historic Review for Addison's Disease Therapeutics by Therapy - Oral Drugs and Parenteral Drugs Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 82: Russia 16-Year Perspective for Addison's Disease Therapeutics by Therapy - Percentage Breakdown of Value Sales for Oral Drugs and Parenteral Drugs for the Years 2014, 2025 & 2030
    • TABLE 83: Russia Recent Past, Current & Future Analysis for Addison's Disease Therapeutics by End-Use - Hospitals & Clinics End-Use and Diagnostic Laboratories End-Use - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 84: Russia Historic Review for Addison's Disease Therapeutics by End-Use - Hospitals & Clinics End-Use and Diagnostic Laboratories End-Use Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 85: Russia 16-Year Perspective for Addison's Disease Therapeutics by End-Use - Percentage Breakdown of Value Sales for Hospitals & Clinics End-Use and Diagnostic Laboratories End-Use for the Years 2014, 2025 & 2030
  • REST OF EUROPE
    • TABLE 86: Rest of Europe Recent Past, Current & Future Analysis for Addison's Disease Therapeutics by Therapy - Oral Drugs and Parenteral Drugs - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 87: Rest of Europe Historic Review for Addison's Disease Therapeutics by Therapy - Oral Drugs and Parenteral Drugs Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 88: Rest of Europe 16-Year Perspective for Addison's Disease Therapeutics by Therapy - Percentage Breakdown of Value Sales for Oral Drugs and Parenteral Drugs for the Years 2014, 2025 & 2030
    • TABLE 89: Rest of Europe Recent Past, Current & Future Analysis for Addison's Disease Therapeutics by End-Use - Hospitals & Clinics End-Use and Diagnostic Laboratories End-Use - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 90: Rest of Europe Historic Review for Addison's Disease Therapeutics by End-Use - Hospitals & Clinics End-Use and Diagnostic Laboratories End-Use Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 91: Rest of Europe 16-Year Perspective for Addison's Disease Therapeutics by End-Use - Percentage Breakdown of Value Sales for Hospitals & Clinics End-Use and Diagnostic Laboratories End-Use for the Years 2014, 2025 & 2030
  • ASIA-PACIFIC
    • Addison's Disease Therapeutics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Asia-Pacific for 2025 (E)
    • TABLE 92: Asia-Pacific Recent Past, Current & Future Analysis for Addison's Disease Therapeutics by Geographic Region - Australia, India, South Korea and Rest of Asia-Pacific Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 93: Asia-Pacific Historic Review for Addison's Disease Therapeutics by Geographic Region - Australia, India, South Korea and Rest of Asia-Pacific Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 94: Asia-Pacific 16-Year Perspective for Addison's Disease Therapeutics by Geographic Region - Percentage Breakdown of Value Sales for Australia, India, South Korea and Rest of Asia-Pacific Markets for Years 2014, 2025 & 2030
    • TABLE 95: Asia-Pacific Recent Past, Current & Future Analysis for Addison's Disease Therapeutics by Therapy - Oral Drugs and Parenteral Drugs - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 96: Asia-Pacific Historic Review for Addison's Disease Therapeutics by Therapy - Oral Drugs and Parenteral Drugs Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 97: Asia-Pacific 16-Year Perspective for Addison's Disease Therapeutics by Therapy - Percentage Breakdown of Value Sales for Oral Drugs and Parenteral Drugs for the Years 2014, 2025 & 2030
    • TABLE 98: Asia-Pacific Recent Past, Current & Future Analysis for Addison's Disease Therapeutics by End-Use - Hospitals & Clinics End-Use and Diagnostic Laboratories End-Use - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 99: Asia-Pacific Historic Review for Addison's Disease Therapeutics by End-Use - Hospitals & Clinics End-Use and Diagnostic Laboratories End-Use Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 100: Asia-Pacific 16-Year Perspective for Addison's Disease Therapeutics by End-Use - Percentage Breakdown of Value Sales for Hospitals & Clinics End-Use and Diagnostic Laboratories End-Use for the Years 2014, 2025 & 2030
  • AUSTRALIA
    • Addison's Disease Therapeutics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Australia for 2025 (E)
    • TABLE 101: Australia Recent Past, Current & Future Analysis for Addison's Disease Therapeutics by Therapy - Oral Drugs and Parenteral Drugs - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 102: Australia Historic Review for Addison's Disease Therapeutics by Therapy - Oral Drugs and Parenteral Drugs Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 103: Australia 16-Year Perspective for Addison's Disease Therapeutics by Therapy - Percentage Breakdown of Value Sales for Oral Drugs and Parenteral Drugs for the Years 2014, 2025 & 2030
    • TABLE 104: Australia Recent Past, Current & Future Analysis for Addison's Disease Therapeutics by End-Use - Hospitals & Clinics End-Use and Diagnostic Laboratories End-Use - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 105: Australia Historic Review for Addison's Disease Therapeutics by End-Use - Hospitals & Clinics End-Use and Diagnostic Laboratories End-Use Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 106: Australia 16-Year Perspective for Addison's Disease Therapeutics by End-Use - Percentage Breakdown of Value Sales for Hospitals & Clinics End-Use and Diagnostic Laboratories End-Use for the Years 2014, 2025 & 2030
  • INDIA
    • Addison's Disease Therapeutics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in India for 2025 (E)
    • TABLE 107: India Recent Past, Current & Future Analysis for Addison's Disease Therapeutics by Therapy - Oral Drugs and Parenteral Drugs - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 108: India Historic Review for Addison's Disease Therapeutics by Therapy - Oral Drugs and Parenteral Drugs Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 109: India 16-Year Perspective for Addison's Disease Therapeutics by Therapy - Percentage Breakdown of Value Sales for Oral Drugs and Parenteral Drugs for the Years 2014, 2025 & 2030
    • TABLE 110: India Recent Past, Current & Future Analysis for Addison's Disease Therapeutics by End-Use - Hospitals & Clinics End-Use and Diagnostic Laboratories End-Use - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 111: India Historic Review for Addison's Disease Therapeutics by End-Use - Hospitals & Clinics End-Use and Diagnostic Laboratories End-Use Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 112: India 16-Year Perspective for Addison's Disease Therapeutics by End-Use - Percentage Breakdown of Value Sales for Hospitals & Clinics End-Use and Diagnostic Laboratories End-Use for the Years 2014, 2025 & 2030
  • SOUTH KOREA
    • TABLE 113: South Korea Recent Past, Current & Future Analysis for Addison's Disease Therapeutics by Therapy - Oral Drugs and Parenteral Drugs - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 114: South Korea Historic Review for Addison's Disease Therapeutics by Therapy - Oral Drugs and Parenteral Drugs Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 115: South Korea 16-Year Perspective for Addison's Disease Therapeutics by Therapy - Percentage Breakdown of Value Sales for Oral Drugs and Parenteral Drugs for the Years 2014, 2025 & 2030
    • TABLE 116: South Korea Recent Past, Current & Future Analysis for Addison's Disease Therapeutics by End-Use - Hospitals & Clinics End-Use and Diagnostic Laboratories End-Use - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 117: South Korea Historic Review for Addison's Disease Therapeutics by End-Use - Hospitals & Clinics End-Use and Diagnostic Laboratories End-Use Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 118: South Korea 16-Year Perspective for Addison's Disease Therapeutics by End-Use - Percentage Breakdown of Value Sales for Hospitals & Clinics End-Use and Diagnostic Laboratories End-Use for the Years 2014, 2025 & 2030
  • REST OF ASIA-PACIFIC
    • TABLE 119: Rest of Asia-Pacific Recent Past, Current & Future Analysis for Addison's Disease Therapeutics by Therapy - Oral Drugs and Parenteral Drugs - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 120: Rest of Asia-Pacific Historic Review for Addison's Disease Therapeutics by Therapy - Oral Drugs and Parenteral Drugs Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 121: Rest of Asia-Pacific 16-Year Perspective for Addison's Disease Therapeutics by Therapy - Percentage Breakdown of Value Sales for Oral Drugs and Parenteral Drugs for the Years 2014, 2025 & 2030
    • TABLE 122: Rest of Asia-Pacific Recent Past, Current & Future Analysis for Addison's Disease Therapeutics by End-Use - Hospitals & Clinics End-Use and Diagnostic Laboratories End-Use - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 123: Rest of Asia-Pacific Historic Review for Addison's Disease Therapeutics by End-Use - Hospitals & Clinics End-Use and Diagnostic Laboratories End-Use Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 124: Rest of Asia-Pacific 16-Year Perspective for Addison's Disease Therapeutics by End-Use - Percentage Breakdown of Value Sales for Hospitals & Clinics End-Use and Diagnostic Laboratories End-Use for the Years 2014, 2025 & 2030
  • LATIN AMERICA
    • Addison's Disease Therapeutics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Latin America for 2025 (E)
    • TABLE 125: Latin America Recent Past, Current & Future Analysis for Addison's Disease Therapeutics by Geographic Region - Argentina, Brazil, Mexico and Rest of Latin America Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 126: Latin America Historic Review for Addison's Disease Therapeutics by Geographic Region - Argentina, Brazil, Mexico and Rest of Latin America Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 127: Latin America 16-Year Perspective for Addison's Disease Therapeutics by Geographic Region - Percentage Breakdown of Value Sales for Argentina, Brazil, Mexico and Rest of Latin America Markets for Years 2014, 2025 & 2030
    • TABLE 128: Latin America Recent Past, Current & Future Analysis for Addison's Disease Therapeutics by Therapy - Oral Drugs and Parenteral Drugs - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 129: Latin America Historic Review for Addison's Disease Therapeutics by Therapy - Oral Drugs and Parenteral Drugs Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 130: Latin America 16-Year Perspective for Addison's Disease Therapeutics by Therapy - Percentage Breakdown of Value Sales for Oral Drugs and Parenteral Drugs for the Years 2014, 2025 & 2030
    • TABLE 131: Latin America Recent Past, Current & Future Analysis for Addison's Disease Therapeutics by End-Use - Hospitals & Clinics End-Use and Diagnostic Laboratories End-Use - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 132: Latin America Historic Review for Addison's Disease Therapeutics by End-Use - Hospitals & Clinics End-Use and Diagnostic Laboratories End-Use Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 133: Latin America 16-Year Perspective for Addison's Disease Therapeutics by End-Use - Percentage Breakdown of Value Sales for Hospitals & Clinics End-Use and Diagnostic Laboratories End-Use for the Years 2014, 2025 & 2030
  • ARGENTINA
    • TABLE 134: Argentina Recent Past, Current & Future Analysis for Addison's Disease Therapeutics by Therapy - Oral Drugs and Parenteral Drugs - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 135: Argentina Historic Review for Addison's Disease Therapeutics by Therapy - Oral Drugs and Parenteral Drugs Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 136: Argentina 16-Year Perspective for Addison's Disease Therapeutics by Therapy - Percentage Breakdown of Value Sales for Oral Drugs and Parenteral Drugs for the Years 2014, 2025 & 2030
    • TABLE 137: Argentina Recent Past, Current & Future Analysis for Addison's Disease Therapeutics by End-Use - Hospitals & Clinics End-Use and Diagnostic Laboratories End-Use - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 138: Argentina Historic Review for Addison's Disease Therapeutics by End-Use - Hospitals & Clinics End-Use and Diagnostic Laboratories End-Use Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 139: Argentina 16-Year Perspective for Addison's Disease Therapeutics by End-Use - Percentage Breakdown of Value Sales for Hospitals & Clinics End-Use and Diagnostic Laboratories End-Use for the Years 2014, 2025 & 2030
  • BRAZIL
    • TABLE 140: Brazil Recent Past, Current & Future Analysis for Addison's Disease Therapeutics by Therapy - Oral Drugs and Parenteral Drugs - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 141: Brazil Historic Review for Addison's Disease Therapeutics by Therapy - Oral Drugs and Parenteral Drugs Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 142: Brazil 16-Year Perspective for Addison's Disease Therapeutics by Therapy - Percentage Breakdown of Value Sales for Oral Drugs and Parenteral Drugs for the Years 2014, 2025 & 2030
    • TABLE 143: Brazil Recent Past, Current & Future Analysis for Addison's Disease Therapeutics by End-Use - Hospitals & Clinics End-Use and Diagnostic Laboratories End-Use - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 144: Brazil Historic Review for Addison's Disease Therapeutics by End-Use - Hospitals & Clinics End-Use and Diagnostic Laboratories End-Use Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 145: Brazil 16-Year Perspective for Addison's Disease Therapeutics by End-Use - Percentage Breakdown of Value Sales for Hospitals & Clinics End-Use and Diagnostic Laboratories End-Use for the Years 2014, 2025 & 2030
  • MEXICO
    • TABLE 146: Mexico Recent Past, Current & Future Analysis for Addison's Disease Therapeutics by Therapy - Oral Drugs and Parenteral Drugs - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 147: Mexico Historic Review for Addison's Disease Therapeutics by Therapy - Oral Drugs and Parenteral Drugs Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 148: Mexico 16-Year Perspective for Addison's Disease Therapeutics by Therapy - Percentage Breakdown of Value Sales for Oral Drugs and Parenteral Drugs for the Years 2014, 2025 & 2030
    • TABLE 149: Mexico Recent Past, Current & Future Analysis for Addison's Disease Therapeutics by End-Use - Hospitals & Clinics End-Use and Diagnostic Laboratories End-Use - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 150: Mexico Historic Review for Addison's Disease Therapeutics by End-Use - Hospitals & Clinics End-Use and Diagnostic Laboratories End-Use Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 151: Mexico 16-Year Perspective for Addison's Disease Therapeutics by End-Use - Percentage Breakdown of Value Sales for Hospitals & Clinics End-Use and Diagnostic Laboratories End-Use for the Years 2014, 2025 & 2030
  • REST OF LATIN AMERICA
    • TABLE 152: Rest of Latin America Recent Past, Current & Future Analysis for Addison's Disease Therapeutics by Therapy - Oral Drugs and Parenteral Drugs - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 153: Rest of Latin America Historic Review for Addison's Disease Therapeutics by Therapy - Oral Drugs and Parenteral Drugs Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 154: Rest of Latin America 16-Year Perspective for Addison's Disease Therapeutics by Therapy - Percentage Breakdown of Value Sales for Oral Drugs and Parenteral Drugs for the Years 2014, 2025 & 2030
    • TABLE 155: Rest of Latin America Recent Past, Current & Future Analysis for Addison's Disease Therapeutics by End-Use - Hospitals & Clinics End-Use and Diagnostic Laboratories End-Use - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 156: Rest of Latin America Historic Review for Addison's Disease Therapeutics by End-Use - Hospitals & Clinics End-Use and Diagnostic Laboratories End-Use Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 157: Rest of Latin America 16-Year Perspective for Addison's Disease Therapeutics by End-Use - Percentage Breakdown of Value Sales for Hospitals & Clinics End-Use and Diagnostic Laboratories End-Use for the Years 2014, 2025 & 2030
  • MIDDLE EAST
    • Addison's Disease Therapeutics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Middle East for 2025 (E)
    • TABLE 158: Middle East Recent Past, Current & Future Analysis for Addison's Disease Therapeutics by Geographic Region - Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 159: Middle East Historic Review for Addison's Disease Therapeutics by Geographic Region - Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 160: Middle East 16-Year Perspective for Addison's Disease Therapeutics by Geographic Region - Percentage Breakdown of Value Sales for Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets for Years 2014, 2025 & 2030
    • TABLE 161: Middle East Recent Past, Current & Future Analysis for Addison's Disease Therapeutics by Therapy - Oral Drugs and Parenteral Drugs - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 162: Middle East Historic Review for Addison's Disease Therapeutics by Therapy - Oral Drugs and Parenteral Drugs Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 163: Middle East 16-Year Perspective for Addison's Disease Therapeutics by Therapy - Percentage Breakdown of Value Sales for Oral Drugs and Parenteral Drugs for the Years 2014, 2025 & 2030
    • TABLE 164: Middle East Recent Past, Current & Future Analysis for Addison's Disease Therapeutics by End-Use - Hospitals & Clinics End-Use and Diagnostic Laboratories End-Use - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 165: Middle East Historic Review for Addison's Disease Therapeutics by End-Use - Hospitals & Clinics End-Use and Diagnostic Laboratories End-Use Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 166: Middle East 16-Year Perspective for Addison's Disease Therapeutics by End-Use - Percentage Breakdown of Value Sales for Hospitals & Clinics End-Use and Diagnostic Laboratories End-Use for the Years 2014, 2025 & 2030
  • IRAN
    • TABLE 167: Iran Recent Past, Current & Future Analysis for Addison's Disease Therapeutics by Therapy - Oral Drugs and Parenteral Drugs - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 168: Iran Historic Review for Addison's Disease Therapeutics by Therapy - Oral Drugs and Parenteral Drugs Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 169: Iran 16-Year Perspective for Addison's Disease Therapeutics by Therapy - Percentage Breakdown of Value Sales for Oral Drugs and Parenteral Drugs for the Years 2014, 2025 & 2030
    • TABLE 170: Iran Recent Past, Current & Future Analysis for Addison's Disease Therapeutics by End-Use - Hospitals & Clinics End-Use and Diagnostic Laboratories End-Use - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 171: Iran Historic Review for Addison's Disease Therapeutics by End-Use - Hospitals & Clinics End-Use and Diagnostic Laboratories End-Use Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 172: Iran 16-Year Perspective for Addison's Disease Therapeutics by End-Use - Percentage Breakdown of Value Sales for Hospitals & Clinics End-Use and Diagnostic Laboratories End-Use for the Years 2014, 2025 & 2030
  • ISRAEL
    • TABLE 173: Israel Recent Past, Current & Future Analysis for Addison's Disease Therapeutics by Therapy - Oral Drugs and Parenteral Drugs - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 174: Israel Historic Review for Addison's Disease Therapeutics by Therapy - Oral Drugs and Parenteral Drugs Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 175: Israel 16-Year Perspective for Addison's Disease Therapeutics by Therapy - Percentage Breakdown of Value Sales for Oral Drugs and Parenteral Drugs for the Years 2014, 2025 & 2030
    • TABLE 176: Israel Recent Past, Current & Future Analysis for Addison's Disease Therapeutics by End-Use - Hospitals & Clinics End-Use and Diagnostic Laboratories End-Use - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 177: Israel Historic Review for Addison's Disease Therapeutics by End-Use - Hospitals & Clinics End-Use and Diagnostic Laboratories End-Use Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 178: Israel 16-Year Perspective for Addison's Disease Therapeutics by End-Use - Percentage Breakdown of Value Sales for Hospitals & Clinics End-Use and Diagnostic Laboratories End-Use for the Years 2014, 2025 & 2030
  • SAUDI ARABIA
    • TABLE 179: Saudi Arabia Recent Past, Current & Future Analysis for Addison's Disease Therapeutics by Therapy - Oral Drugs and Parenteral Drugs - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 180: Saudi Arabia Historic Review for Addison's Disease Therapeutics by Therapy - Oral Drugs and Parenteral Drugs Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 181: Saudi Arabia 16-Year Perspective for Addison's Disease Therapeutics by Therapy - Percentage Breakdown of Value Sales for Oral Drugs and Parenteral Drugs for the Years 2014, 2025 & 2030
    • TABLE 182: Saudi Arabia Recent Past, Current & Future Analysis for Addison's Disease Therapeutics by End-Use - Hospitals & Clinics End-Use and Diagnostic Laboratories End-Use - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 183: Saudi Arabia Historic Review for Addison's Disease Therapeutics by End-Use - Hospitals & Clinics End-Use and Diagnostic Laboratories End-Use Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 184: Saudi Arabia 16-Year Perspective for Addison's Disease Therapeutics by End-Use - Percentage Breakdown of Value Sales for Hospitals & Clinics End-Use and Diagnostic Laboratories End-Use for the Years 2014, 2025 & 2030
  • UNITED ARAB EMIRATES
    • TABLE 185: UAE Recent Past, Current & Future Analysis for Addison's Disease Therapeutics by Therapy - Oral Drugs and Parenteral Drugs - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 186: UAE Historic Review for Addison's Disease Therapeutics by Therapy - Oral Drugs and Parenteral Drugs Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 187: UAE 16-Year Perspective for Addison's Disease Therapeutics by Therapy - Percentage Breakdown of Value Sales for Oral Drugs and Parenteral Drugs for the Years 2014, 2025 & 2030
    • TABLE 188: UAE Recent Past, Current & Future Analysis for Addison's Disease Therapeutics by End-Use - Hospitals & Clinics End-Use and Diagnostic Laboratories End-Use - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 189: UAE Historic Review for Addison's Disease Therapeutics by End-Use - Hospitals & Clinics End-Use and Diagnostic Laboratories End-Use Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 190: UAE 16-Year Perspective for Addison's Disease Therapeutics by End-Use - Percentage Breakdown of Value Sales for Hospitals & Clinics End-Use and Diagnostic Laboratories End-Use for the Years 2014, 2025 & 2030
  • REST OF MIDDLE EAST
    • TABLE 191: Rest of Middle East Recent Past, Current & Future Analysis for Addison's Disease Therapeutics by Therapy - Oral Drugs and Parenteral Drugs - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 192: Rest of Middle East Historic Review for Addison's Disease Therapeutics by Therapy - Oral Drugs and Parenteral Drugs Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 193: Rest of Middle East 16-Year Perspective for Addison's Disease Therapeutics by Therapy - Percentage Breakdown of Value Sales for Oral Drugs and Parenteral Drugs for the Years 2014, 2025 & 2030
    • TABLE 194: Rest of Middle East Recent Past, Current & Future Analysis for Addison's Disease Therapeutics by End-Use - Hospitals & Clinics End-Use and Diagnostic Laboratories End-Use - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 195: Rest of Middle East Historic Review for Addison's Disease Therapeutics by End-Use - Hospitals & Clinics End-Use and Diagnostic Laboratories End-Use Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 196: Rest of Middle East 16-Year Perspective for Addison's Disease Therapeutics by End-Use - Percentage Breakdown of Value Sales for Hospitals & Clinics End-Use and Diagnostic Laboratories End-Use for the Years 2014, 2025 & 2030
  • AFRICA
    • Addison's Disease Therapeutics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Africa for 2025 (E)
    • TABLE 197: Africa Recent Past, Current & Future Analysis for Addison's Disease Therapeutics by Therapy - Oral Drugs and Parenteral Drugs - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 198: Africa Historic Review for Addison's Disease Therapeutics by Therapy - Oral Drugs and Parenteral Drugs Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 199: Africa 16-Year Perspective for Addison's Disease Therapeutics by Therapy - Percentage Breakdown of Value Sales for Oral Drugs and Parenteral Drugs for the Years 2014, 2025 & 2030
    • TABLE 200: Africa Recent Past, Current & Future Analysis for Addison's Disease Therapeutics by End-Use - Hospitals & Clinics End-Use and Diagnostic Laboratories End-Use - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 201: Africa Historic Review for Addison's Disease Therapeutics by End-Use - Hospitals & Clinics End-Use and Diagnostic Laboratories End-Use Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 202: Africa 16-Year Perspective for Addison's Disease Therapeutics by End-Use - Percentage Breakdown of Value Sales for Hospitals & Clinics End-Use and Diagnostic Laboratories End-Use for the Years 2014, 2025 & 2030

IV. COMPETITION